EyeGate Pharmaceuticals, Inc. logo
EyeGate Pharmaceuticals, Inc. EYEG

EyeGate Pharmaceuticals, Inc. Net Debt 2011-2026 | EYEG

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt EyeGate Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-824 K -3.69 M -8 M -7.79 M -3.61 M -8.39 M 3.04 M 1.53 M -1.94 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.04 M -8.39 M -3.3 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
-973 M $ 97.54 2.14 % $ 27.2 B germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
-132 M $ 8.65 8.19 % $ 85.5 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.63 -2.42 % $ 8.73 B australiaAustralia
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Esperion Therapeutics Esperion Therapeutics
ESPR
-165 M $ 2.14 -1.38 % $ 445 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-3.44 M $ 0.81 -0.07 % $ 27.9 M israelIsrael
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
457 M $ 20.47 0.49 % $ 957 M usaUSA
Genmab A/S Genmab A/S
GMAB
-6.94 B $ 28.2 -0.18 % $ 18 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.19 -0.24 % $ 6.83 B spainSpain
GT Biopharma GT Biopharma
GTBP
-5.5 M $ 0.36 -2.82 % $ 1.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Halozyme Therapeutics Halozyme Therapeutics
HALO
1.27 B $ 67.06 -1.12 % $ 8.04 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
-608 M $ 28.69 -0.69 % $ 1.65 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M $ 1.41 0.71 % $ 363 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 2.96 1.37 % $ 4.87 M israelIsrael
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.16 1.84 % $ 445 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 24.01 -0.85 % $ 3.05 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
3.77 M $ 7.12 1.14 % $ 64.3 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-26.5 M $ 32.24 - $ 2.14 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.48 -0.67 % $ 394 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
-188 M - - $ 1.41 B usaUSA
Incyte Corporation Incyte Corporation
INCY
-3.06 B $ 94.86 -1.26 % $ 18.5 B usaUSA
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.61 2.35 % $ 16.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-32.3 M $ 1.05 4.5 % $ 152 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
9.86 B - - $ 96.9 B britainBritain
Inventiva S.A. Inventiva S.A.
IVA
-95.6 M $ 5.18 -1.52 % $ 138 M franceFrance